| payload |
{"created_at":"2026-04-17T02:13:18.114 {"created_at":"2026-04-17T02:13:18.114675+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:049ad17f8c9e2500","evidence_event_ids":["evt_540d3d898d59"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","company":"Vaxart, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_7c504e6d62cb1527","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","content_type":"text/plain","enriched_at":"2026-04-17T03:42:16.944988+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"vxrt20260414_s3.htm","final_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt","source_event_id":"evt_540d3d898d59","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"S-3","fp":"30e3db9ae68dd422","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["April 15, 2026"],"entities":[{"asset_class":"equity","name":"Vaxart, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"securities_firm","name":"Citizens JMP Securities, LLC","relevance":"medium","symbol":"","type":"underwriter_counterparty"},{"asset_class":"securities_firm","name":"B. Riley Securities, Inc.","relevance":"medium","symbol":"","type":"underwriter_counterparty"},{"asset_class":"company_executive","name":"Steven Lo","relevance":"low","symbol":"","type":"person"},{"asset_class":"law_firm","name":"Faith L. Charles Thompson Hine LLP","relevance":"low","symbol":"","type":"legal_counsel"}],"event_type":"listing","information_gaps":["The provided text does not include the full registration statement details (e.g., exact securities, share counts beyond the $49,772,479 reference, offering mechanics, or risk factors).","The signal metadata lists a filing_date of 2026-04-17T02:13:18.114675+00:00, but the article text states \"As filed ... on April 15, 2026\"; the discrepancy is not explained in the provided text.","No explicit statement is provided about what changed versus a prior known state (e.g., whether this is a new S-3, an amendment, or incremental changes).","No financial guidance or proceeds/uses of proceeds are included in the provided excerpt."],"key_facts":["The document is a Form S-3 registration statement under the Securities Act of 1933 for Vaxart, Inc.","The filing text states it was filed with the SEC on April 15, 2026 (\"As filed with the Securities and Exchange Commission on April 15, 2026\").","The filing contains two documents: a base prospectus and a sales agreement prospectus supplement.","The explanatory note states that $49,772,479 of common stock may be offered, issued, and sold under the sales agreement prospectus supplement.","The explanatory note states that the $49,772,479 included in the sales agreement prospectus supplement is included within $300,000,000 of securities that may be offered, issued, and sold under the base prospectus.","The explanatory note states that upon termination of the sales agreement with Citizens JMP Securities, LLC and B. Riley Securities, Inc., any portion of the $49,772,479 not sold under the sales agreement will be available for sale in other offerings under the base prospectus.","The explanatory note states that if no shares are sold under the sales agreement, the full $300,000,000 of securities may be sold in other offerings under the base prospectus and a corresponding prospectus supplement."],"numeric_claims":[{"label":"common stock amount referenced under sales agreement prospectus supplement","value":"$49,772,479"},{"label":"total securities amount referenced under base prospectus","value":"$300,000,000"}],"primary_claim":"Vaxart, Inc. filed a Form S-3 registration statement with the SEC on April 15, 2026 that includes a base prospectus and a sales agreement prospectus supplement covering up to $300,000,000 of securities (including $49,772,479 of common stock under the sales agreement supplement).","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Vaxart, Inc. filed a Form S-3 registration statement with the SEC on April 15, 2026 (registration statement filed as of that date). The filing includes a base prospectus plus a sales agreement prospectus supplement and references up to $300,000,000 of securities, including $49,772,479 of common stock under the sales agreement prospectus supplement.","topics":["SEC filing","Form S-3","registration statement","prospectus","sales agreement prospectus supplement","common stock offering"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form S-3 \u00b7 Vaxart, Inc. \u00b7 Filed 20260416","ticker":"VXRT","tickers":["VXRT"],"title":"VXRT filed S-3","url":"https://www.sec.gov/Archives/edgar/data/72444/0001437749-26-012471.txt"}}... |